Compare AbbVie Inc (ABBV) vs The Vita Coco Company Inc (COCO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs The Vita Coco Company Inc — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while The Vita Coco Company Inc trades at $67.98 (market cap $3.74B). The key difference: AbbVie Inc is far larger — about 120.3× The Vita Coco Company Inc's market cap, and AbbVie Inc pays a 2.72% dividend while The Vita Coco Company Inc pays none. Which is the better fit depends on your goals.
| ABBV | COCO | |
|---|---|---|
Market Cap | $449.91B | $3.74B |
Sector | Health | Technology |
52-Week High | $261.07 | $84.02 |
52-Week Low | $184.85 | $32.30 |
Enterprise Value | $513.38B | $3.56B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
COCO trades at $66.78, up 0.94% today, with a bullish technical signal driven by oversold RSI readings but bearish moving averages. The company reported strong Q1 2026 EPS of $0.50, beating expectations, and shows robust profitability with a 12.59% net margin and 26.32% ROE. Recent news highlights market dominance in coconut water and expanded partnerships, supporting growth prospects amid a $125 billion market opportunity.
Outlook is positive with a consensus price target of $79.33, implying 19% upside, though high valuation multiples (P/E 48.39) and competitive pressures pose risks. Investors should weigh strong earnings momentum against potential volatility from sector rotation and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About The Vita Coco Company Inc
The Vita Coco Company is a leading functional beverage brand specializing in coconut water. Its portfolio includes its flagship Vita Coco brand, clean energy drinks, and sustainable enhanced water products.
Read more on COCO →
